Valeant Names Executive VP and Chief Financial Officer
Robert L. Rosiello has joined Valeant Pharmaceuticals, an international developer, manufacturer and marketer of pharmaceuticals and medical devices, as Executive Vice President and the new Chief Financial Officer. For the past 30 years he has gained experience leading specialty pharmaceutical companies in the U.S. and Europe at McKinsey & Company, where he was a Senior Partner in charge of the global merger project for his last 10 years there. “I know his tremendous expertise in healthcare and in particular M&A, his unquestioned intellect, and work ethic and integrity will prove to be of great value to the Valeant organization and its shareholders” says J. Michael Pearson, Chairman and Chief Executive Officer, about Rosiello.
HemoShear Names New President
The privately held discovery stage biotechnology company appointed Vincent E. Aurentz, President of HemoShear. Aurentz will be responsible for leading HemoShear’s scientific and business development strategies, as well as public relations and marketing, in addition to his existing business development responsibilities. He will continue to report directly to CEO and Chairman Jim Powers, and will also join HemoShear’s Board of Managers.
Aurentz has more than 25 years of experience in the pharmaceutical and biotech industry as an entrepreneur and pharmaceutical R&D executive. He spent almost nine years with Merck KGaA and Merck Serono, where he was Executive Vice President, Portfolio Development and member of the Executive Management Board as well as Head of Global Business Development. He was also recently Executive Vice President at Quintiles.
Charles Stacey, MD joined Accera, a U.S. company that develops therapies for nervous system disorders, as President and CEO. After entering the healthcare industry as an orthopedic surgeon in London, Dr. Stacey spent years as an investment professional for companies such as Inventages, a healthcare-oriented equity firm.
The clinical-stage biopharmaceutical company appointed Greg Stea to its Board of Directors as a Class II director. Stea recently retired as the Senior Vice President of Commercial Operations of Cubist Pharmaceuticals, and now will work during his tenure to help advance its antibacterial plazomicin, to the commercial stage.
The specialty pharmaceutical company appointed Sanjay Kakkar, MD, MSc, MPH as CEO. With more than 20 years of experience in global, high-growth enterprises and a successful track record in human health novel technologies, Dr. Kakkar is uniquely suited to the advancement of Armetheon’s oral anticoagulant tecarfarin.
Cypher Genomics, Inc.
The genetic information provider, has announced Catherine J. “Kitty” Mackey, PhD is joining their Scientific Advisory Board. Dr. Mackey currently serves as CEO at CYPrus Therapeutics and was previously Senior Vice President of Worldwide Research and Development for Pfizer, Inc. and director of Pfizer La Jolla. Dr. Mackey has 33 years’ experience building healthcare research and development teams.
The communications agency announced that Larry Wolheim, Principal and Co-founder retired. Wolheim co-founded the company in 2002 with just three partners—200 professionals now work at the company. Previously, he co-founded BioCore Communications and the agency now known as FCB Healthcare.
Halozyme Therapeutics, Inc.
The oncology biotech company named Laurie Stelzer its new Chief Financial Officer. Stelzer has more than 15 years of senior financing experience, most recently serving as Senior Vice President of Finance for R&D, Technical Operations and Business Development at Shire. Stelzer will lead the company as they prepare for approval of their new drug, PEGH20, in the U.S. and Europe.
Michael McKelvey, PhD was appointed President, inVentiv Health Clinical Division and Executive Vice President, inVentiv Health. Prior to joining the company, he served as EVP and Chief Operating Officer at Aptiv Solutions. His previous work experiences include life sciences, pharmaceutical and the global healthcare technology industries.
The clinical stage biopharmaceutical company appointed Martin J. Birkhofer, MD as Chief Medical Officer. Dr Birkhofer, an oncologist by training, joins NuCana from inVentiv Health Clinical. He also previously served in various leadership roles within Research and Development and Business Development at Bristol-Myers Squibb, including Vice President Oncology Global Medical Affairs and Vice President Product Development for Erbitux.
ProNAi Therapeutics, Inc.
The clinical-stage oncology company appointed Barbara Klencke, MD, as Chief Development Officer. The doctor is an accomplished onclolgy drug developer. Previously, she served as the Senior Vice President, Development at Onyx Pharmaceuticals, a subsidiary of Amgen Inc., and Group Medical Director in Product Development, Oncology at Genentech, Inc.
The company dedicated to developing and marketing innovative specialty medicines for those with life-altering conditions, appointed Olivier Bohuon to its Board of Directors as a Non-Executive Director and a member of the Science and Technology Committee of the Shire Board. He has extensive international business and leadership experience across a number of pharmaceutical and healthcare companies in Europe, the Middle East and U.S. He also serves as a Non-Executive Director of Virbac Group SA and is a member of the Smith & Nephew Board of Directors.
Sudler & Hennessey
Amy Duda, EVP, Director of Strategic Planning and Market Analytics at Sudler New York recently presented at the Cannes Lions Festival. She discussed how data and statistics are relevant to health apps and wearable technology. Her expertise includes a focus on oncology, with an emphasis on U.S. and global launches, clinical trials and research.
Turing Pharmaceuticals AG
Turing Pharmaceuticals has announced Eliseo Oreste Salinas, MD, MSc, President of Research and Development. Dr. Salinas brings extensive experience in leading research programs for disorders such as Parkinson’s, attention deficit disorder and Alzheimer’s disease. Previously, he served as President and Chief Scientific Officer of Relmada Therapeutics. At Turing, he will begin trials for ketamine to treat severe depression.